Atossa Genetics Inc (ATOS) 1.91 $ATOS Atossa Genetics

New Post Public Reply Private Reply Replies (0) Message Board

Mar 30, 2015 at 5:28 PM

Atossa Genetics Inc (ATOS) 1.91 $ATOS

Atossa Genetics reports FY'14 results
Seeking Alpha - at Seeking Alpha - 1 hr 22 mins ago

ATOS: 1.91 (+0.13)

Atossa Genetics Announces 2014 Financial Results and Provides Company Update
Marketwired - 1 hr 26 mins ago
Atossa Genetics, Inc. (NASDAQ: ATOS) today announced 2014 financial results and provided an update on recent company developments.
ATOS: 1.91 (+0.13)

Atossa Genetics to Host 2014 Financial Results and Company Update Conference Call on Monday, March 30, 2015
Marketwired - Thu Mar 26, 7:00AM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will host a conference call on Monday, March 30, 2015 at 4:30 pm Eastern Time to review 2014 financial results and a company update. Following management's formal remarks, there will be a question and answer session.
ATOS: 1.91 (+0.13)

"How Does Breast Cancer Develop?" Pilot Grants Awarded to Multidisciplinary Teams Using the Intraductal Approach to Advance Breast Cancer Prevention
Business Wire - Tue Mar 24, 10:24AM CDT
Dr. Susan Love Research Foundation awarded four innovative pilot grants to research projects that will explore using next generation technology to investigate the human breast and how it develops cancer. Three of the pilot grants awarded at Dr. Susan Love Research Foundation's 8th International Symposium on the Breast are funded by the Susan G. Komen breast cancer organization. The fourth grant is funded by Atossa Genetics (NASDAQ: ATOS).
ATOS: 1.91 (+0.13)

Atossa launches breast aspirator in U.S.
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 9:00AM CDT

ATOS: 1.91 (+0.13)

Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 8:18AM CDT

ABMD: 73.47 (+3.16), WLL: 30.72 (+0.22), JRJC: 4.50 (unch), VCEL: 3.73 (-0.03), RADA: 2.59 (+0.19), HPJ: 3.84 (-0.05), ISR: 1.61 (-0.05), SONS: 7.96 (-0.04), ARAY: 9.31 (+0.01), ATOS: 1.91 (+0.13), GNVC: 2.94 (-0.16), SAAS: 10.98 (+0.01), HOTR: 2.48 (+0.12), DGLY: 13.36 (+0.69), IDN: 1.54 (unch)

Atossa Genetics Launches the FullCYTE Breast Aspirator in the United States
Marketwired - Tue Mar 24, 7:02AM CDT
Atossa Genetics Inc. (NASDAQ: ATOS), announced today that it has launched the FullCYTE Breast Aspirator in the United States.
ATOS: 1.91 (+0.13)

Atossa Genetics launches breast cancer products in Europe
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 8:07AM CST

ATOS: 1.91 (+0.13)

Nasdaq stocks posting largest volume increases
AP - Fri Feb 27, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ATOS: 1.91 (+0.13), UNXL: 7.00 (-0.01), CYCC: 0.92 (+0.02), CYTX: 1.20 (+0.01), TBIO: 1.45 (-0.06), LKQ: 24.98 (+0.21), QBAK: 1.49 (unch), ESSX: 1.39 (+0.06), BWFG: 19.50 (unch), ONFC: 19.75 (+0.22), CYBX: 64.99 (+0.12)

Most active Nasdaq-traded stocks
AP - Fri Feb 27, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
FB: 83.19 (-0.11), INTC: 31.46 (-0.54), ATOS: 1.91 (+0.13), HERO: 0.45 (-0.02), FOX: 33.15 (+0.41), CYCC: 0.92 (+0.02), CYTX: 1.20 (+0.01), AMAT: 22.77 (-0.06), FOXA: 34.26 (+0.56), ARCP: 9.85 (-0.05), ZNGA: 2.78 (+0.01), MSFT: 40.96 (-0.01), AAPL: 126.37 (+3.12), CSCO: 27.65 (+0.52)

Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.11 (-0.05), VRX: 201.38 (+3.54), ACT: 304.76 (+1.20), PCYC: 256.43 (-0.12), MDT: 78.42 (+1.04), CAH: 90.80 (+0.71), CLDX: 27.84 (+0.67), HSP: 87.72 (-0.16), AGN: 240.22 (+2.88), JNJ: 101.55 (+1.21), ATOS: 1.91 (+0.13), ONVO: 3.37 (-0.29), PTCT: 64.85 (+2.23), SNY: 50.24 (+0.27), PTLA: 38.50 (-0.16), INCY: 94.19 (-0.17), PFE: 35.00 (+0.47), CPHR: 9.45 (-0.43), MYL: 60.00 (-1.63), AMGN: 164.30 (+1.71), LLY: 73.87 (+0.29), BMY: 65.76 (+0.50), MNKD: 5.34 (+0.10), NKTR: 11.31 (+0.22), OMER: 22.39 (+0.53), DVA: 82.17 (+0.34), GILD: 100.69 (-0.31), SGEN: 36.10 (-0.12), ACHN: 10.24 (+0.08), MRK: 58.34 (+0.59), TEVA: 62.52 (+0.54), BIL: 45.71 (-0.01), ARIA: 8.56 (+0.17), NVS: 101.31 (+0.91)

Atossa Genetics: Spotty Track Record And Short On Cash
Probio Invest - at Seeking Alpha - Thu Feb 26, 1:22PM CST

ATOS: 1.91 (+0.13)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 11:57AM CST

FRO: 2.23 (-0.14), HAWKB: 34.84 (-0.11), ARQL: 2.24 (+0.14), MNDO: 3.25 (-0.10), BIOC: 2.34 (+0.21), MRGE: 4.54 (+0.21), CYBX: 64.99 (+0.12), CWEI: 50.17 (+0.56), ELX: 7.97 (unch), ATOS: 1.91 (+0.13), IQNT: 15.82 (-0.14), FLML: 18.02 (+0.02), ONE: 2.33 (+0.02), CLRX: 1.05 (-0.02), PGTI: 11.23 (+0.35), ESSX: 1.39 (+0.06), HMNY: 2.42 (unch), TASR: 24.63 (+0.56), MSLI: 2.08 (-0.05), UIL: 50.83 (+0.59)

Atossa up premarket on deal with leading medical products distributor
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 7:12AM CST

ATOS: 1.91 (+0.13), HSIC: 140.84 (+2.04)

Genetic Technologies Remains Among Most Difficult To Borrow Names
Interactive Brokers - at Seeking Alpha - Tue Feb 24, 12:46AM CST
Genetic Technologies Limited (NASDAQ: GENE ) continues to be one of the most sought after borrows, and while liquidity remains scarce, what little supply is available to borrow is expensive. Although the price of GENE shares has come down...
GPRO: 43.58 (+0.88), TSLA: 190.57 (+5.57), CYBR: 54.82 (+2.59), MNKD: 5.34 (+0.10), GENE: 4.95 (+1.25), BLDP: 2.02 (-0.01), WPRT: 4.05 (+0.02), ATOS: 1.91 (+0.13), SGNL: 2.26 (-0.10), RIG: 14.71 (+0.22), OPK: 14.71 (+0.22), PSTR: 1.82 (-0.35), LINE: 11.30 (-0.27), ZU: 13.37 (+0.44)

4 Biotech Stocks Under $10 to Trade for Breakouts: Sophiris, Atossa and More
at The Street - Tue Feb 17, 12:20PM CST
Keep these under-$10 biotech stocks on your breakout trading radar.
ATOS: 1.91 (+0.13), SPHS: 0.55 (-0.04), ARWR: 7.00 (+0.02), ADHD: 5.98 (-0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

Maven Pet's AI Paw-tnership: Changing Pet Care Landscape

AI in the World of Doggie Docs In today's tech-driven world, pet owners are turning to artificial intelligence like never before. Forget flipping through outdated dog-care books—nearly half of us are drilling ChatGPT for health tips on our four-legged pals. Yes, it seems we’re asking an AI about Rover's health more than some other major life decisions. But let's face...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Laars Welcomes Women in Manufacturing to Facility Tour

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...